Cadila Healthcare stands out in pharma pack; expect co to clock 35-36% growth: Hemang Jani

In a chat with ET Now, Hemang Jani, Senior VP, Sharekhan, shares the rationale behind his preference for Cadila Healthcare.

ET Now: Why do you like Cadila?

Hemang Jani: I like Cadila because despite the gloom and doom that we are seeing the pharma space, it is among few companies that stand out. The company is likely to have one big molecule launch on Hepatitis C either December or January. Apart from that, there are about 58-59 different ANDAs that the company will launch in the US. We are expecting the drugmaker to report about 35-36 per cent growth over next two years. Hence, we like the company.